Contact | Print version | PDF version | Send article | RSS feed

Positive results from phase I clinical trial of SMT D002 for the treatment of Seborrhoea

SMT D002 suppresses sebum levels by 90% in repeat-dose trial

22 Apr 2008 - Summit Corporation plc announced a positive outcome from its repeat-dose Phase I clinical trial of SMT D002, its candidate for the treatment of seborrhoea (excessive sebum production), a primary cause of acne.
 
The study was conducted in 18 healthy volunteers and examined the effect of repeat oral doses of SMT D002 over a four-day period. The key findings of the Phase I clinical trial are:
 
- Statistically significant levels of sebum suppression (primary endpoint) of 90% when compared to the placebo group (p=0.04)
 
- SMT D002 proved to be safe with no serious or unexpected adverse side-effects reported
 
- Sebum levels measured over six hours following treatment using a Sebumeter, an industry accepted method
 
- Results from trial support a previous positive Phase I single-dose study conducted in nine volunteers
 
The results of this trial confirm the potential of SMT D002 as a new therapeutic agent for the treatment of seborrhoea in acne patients. Summit plans to develop a topical formulation of SMT D002 to further evaluate its efficacy in the treatment of acne and the Company is actively seeking a commercial partner to advance this candidate from the clinic through to the market.